The sequential method used to determine the effective dose of ciprofol combined with remifentanil in laser surgery of great saphenous vein and cystoscopy without muscle release of the laryngeal mask

Optimal dose of ciprofol combined with remifentanil for laryngeal mask placement without muscle relaxant: a biased-coin up-and-down sequential allocation trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200062686

Enrollment

Unknown

Registered

2022-08-15

Start date

2022-08-01

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Optimal dose of narcotic drug compatibility

Interventions

Case series:None

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Sign a dated informed consent form; 2. Commit to abide by the research procedures and cooperate with the implementation of the whole process of research; 3. Aged > 18 years; 4. ASA grade I-II, no cardiopulmonary disease, no gastroesophageal reflux disease; 5. The operation can be performed under anesthesia and the laryngeal mask is placed, and there is no high requirement for muscle relaxation.

Exclusion criteria

Exclusion criteria: 1. Being pregnant or breastfeeding; 2. Allergic to narcotic drugs; 3. Enrolled in other investigational drugs during the first 6 months of the study period; 4. Patients with gastroesophageal reflux disease, respiratory sleep apnea, BMI > 30, or food intake on the day of surgery.

Design outcomes

Primary

Measure	Time frame
Monitoring of electroencephalo-graph;Heart rate;Intubation reflection;Ventilation parameters;	—

Countries

China

Contacts

Public ContactLuo Yan

Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine

ly11087@rjh.com.cn+86 15921495485

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 15, 2026